ledipasvir/sofosbuvir / Generic mfg. - LARVOL DELTA

Breaking Bad Cells: Histotripsy as a Noninvasive Weapon Against Hepatocellular Carcinoma (ACG 2026) - "Case Description/ Our case presents a 73-year-old female with HCC and a history of hepatitis C treated with ledipasvir/sofosbuvir who underwent elective histotripsy under interventional radiology guidance...As procedural and clinical experience grows, further research is needed to standardize treatment protocols, determine its limitations, and uncover long-term oncologic outcomes. Figure: Figure A: Intraoperative ultrasound of the hepatic lesion Figure: Figure B: Post-operative CT abdomen/pelvis 1 day following histotripsy demonstrates circular zone of treatment with post-procedure reactive changes around the gallbladder fossa"

Non-invasive • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Liver Failure • Oncology • Respiratory Diseases • Solid Tumor • Thrombocytopenia

Hepatitis C Auto-Reinfection Following Autologous Stem Cell Transplantation (ACG 2026) - "Once all-oral direct-acting antiviral (DAA) therapy became available, his HCV was successfully treated with an 8-week course of ledipasvir/sofosbuvir...Fortunately, HCV is easily treatable with DAA therapy and should not be a contraindication to considering ASCT. This case mimics our safe and established experience in solid organ transplantation with HCV-positive donors followed by HCV treatment."

Hematological Malignancies • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Multiple Myeloma • Solid Organ Transplantation • Transplantation

Prior Decompensation Events and Outcomes in Patients Treated for Cirrhosis Secondary to Chronic Hepatitis C (ACG 2026) - "This retrospective study evaluated patients' decompensating events prior to initiating treatment and outcomes after SVR (sustained virologic response) using the current guideline recommended treatment regimens of sofosbuvir-velpatasvir (sof-vel) and ledipasvir-sofosbuvir (led-sof) with the addition of ribavirin (rbv). The study comprised a total of 41 patients (32 males). Prior to treatment, 3 patients were Child-Pugh class C and the remaining were Child-Pugh class B, with a mean MELD of 14.5 ± 4.8 . 22 patients (53%) were treated with sof-vel-rbv, 5 with led-sof-rbv, 8 with led-sof, 6 with sof-vel."

Clinical • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Solid Tumor

Trends in Medicare Part D and Medicaid Utilization and Spending on Hepatitis C Direct-Acting Antiviral Agents: 2019â2024 (ACG 2026) - "Glecaprevir/pibrentasvir declined 75.0% ($660M to $165M) and glecaprevir/pibrentasvir was the dominant agent, with spending declining from $1.19B to $692.9M (-41.9%) and claims falling 33.0% (80,940 to 54,252). Substantial declines in utilization and inflation-adjusted spending were observed across both programs. In Medicare Part D, sofosbuvir/velpatasvir remained the most utilized DAA in 2024 (31,431 claims; -24.4%), with spending falling 39.1% ($1.24B to $758M). Ledipasvir/sofosbuvir and elbasvir/grazoprevir experienced near-complete market exit, with spending reductions of 96.1% and 97.3%, respectively."

Medicaid • Medicare • Reimbursement • US reimbursement • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. (PubMed, J Clin Oncol) - "HCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting."

Journal • Hematological Disorders • Hematological Malignancies • Hepatitis C • Hepatology • Indolent Lymphoma • Infectious Disease • Inflammation • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023. (PubMed, J Viral Hepat) - "Sofosbuvir/ledipasvir and glecaprevir/pibrentasvir were the two most common regimens. Despite the large economic impact, the rapid uptake of DAA therapy suggests an active program of case finding and treatment with the goal of HCV elimination in Japan. Whereas the demographics of people receiving DAA therapy changed over time, treatments were provided uniformly across the nation."

HEOR • Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

ELIMINATION OF HCV IN CHILDREN AND YOUNG PEOPLE THROUGH A COLLABORATIVE VIRTUAL NETWORK (ESPGHAN 2026) - "Genotypes 1&3 were commonest; Sofosbuvir/Ledipasvir (Harvoni) prescribed in 76; Sofosbuvir/Velpatasvir (Epclusa) in 65; & Glecaprevir/Pibrentasvir (Maviret) in 16 with >99% clearance at EoT; 1 required re-treatment due to resistance. Treatment success was >99% in those who completed treatment with 100% confirmed SVR 12m. It has enhanced access to anti-viral therapy for CYP preventing long-term liver disease and transmission of HCV making a fundamental contribution to achieving the NHSE target to eliminate HCV in CYP ahead of the WHO 2030 target."

Clinical • Hepatitis C • Hepatology

Human Pegivirus Encephalitis With Brain Detection and Response to Sofosbuvir Ledipasvir. (PubMed, Ann Clin Transl Neurol) - "Following off-label treatment with sofosbuvir/ledipasvir, the patient showed sustained clinical improvement, normalization of CSF findings, and disappearance of detectable HPgV RNA. This observation expands the clinical context of HPgV-1 detection and supports further investigation of its role in central nervous system disease."

Journal • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease

Hepatocellular carcinoma is a viral reservoir during hepatitis C treatment with direct-acting antivirals (EASL 2026) - "Eight patients received sofosbuvir/ledipasvir ± ribavirin, six received sofosbuvir + daclatasvir ± ribavirin and one received sofosbuvir + ribavirin. During treatment of hepatitis C with DAA in cirrhotic patients with viable HCC, HCV persisted longer within HCC tissue than in non-tumoral liver tissue. These findings support the role of HCC as a viral reservoir during treatment of hepatitis C with DAA."

Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor

High efficacy of direct-acting antivirals and significant fibrosis regression in childhood cancer survivors with chronic hepatitis C: a retrospective study (EASL 2026) - "Patients received Sofosbuvir/Ledipasvir (67.1%) or Sofosbuvir/Velpatasvir (28.0%) according to weight-based dosing. DAA therapy is effective and safe in children with a history of malignancy, showing no negative interaction with maintenance chemotherapy. Viral eradication is associated with rapid and significant regression of liver stiffness measurements, suggesting a high potential for reversibility of early fibrotic changes in the pediatric liver. These findings support a "test and treat" strategy for childhood cancer survivors to prevent long-term hepatic morbidity."

Retrospective data • Fibrosis • Hematological Malignancies • Hepatitis C • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor

COVID-19 pandemic had minimal impact on the effort spent on the enhancement programme of treatment coverage for all adult patients with chronic hepatitis C virus (HCV) infection (EASL 2026) - "DAA therapy for HCV was defined with the prescription of sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, elbasvir/grazoprevir, dasabuvir/ombitasvir/ paritaprevir, daclatasvir/asunaprevir or boceprevir. COVID-19 pandemic had minimal impact on the effort spent on the enhancement programme of DAA treatment coverage. It was likely due to the endeavours mentioned in the Hong Kong Hepatitis Action Plan 2020-2024, which had counteracted the negative impact of the COVID-19 pandemic on hepatitis elimination. Founding: This work was supported by the Investigator Sponsored Research of Gilead Sciences (Reference: IN-HK-987-7181)."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease

The oral cholate challenge test detects early hepatic improvement with ledipasvir/sofosbuvir in liver transplant recipients and patients with advanced cirrhosis (EASL 2026) - "In the SOLAR-1 trial, liver transplant (LTx) recipients with fibrosis or cirrhosis and patients with end-stage liver disease (ESLD) received ledipasvir/sofosbuvir plus ribavirin. The favorable early improvements in function in noncirrhotic patients implies a dynamic reversibility of the changes to the hepatic microcirculation with resolution of the necroinflammation. Slower improvement or lack of early improvement in function in advanced disease suggest that longer follow-up may be required to demonstrate recovery. These findings underscore DSI's sensitivity in detecting early functional responses to antiviral therapy across a spectrum of stages of fibrosis and clinical severity."

Clinical • Metastases • Fibrosis • Hepatology • Immunology • Inflammation • Transplantation

Adaptive and simplified model of relinking HCV-Ab positive patients to care in China: a real-world study from Yunnan province (EASL 2026) - "Till December 2025, 85% (1,914/2,249) of patients had initiated antiviral therapy with Sofosbuvir/Velpatasvir (SOF/VEL) or Ledipasvir/Sofosbuvir (LDV/SOF), with ongoing efforts to recall the remaining patients. The predictive model identified key patient subgroups associated with low treatment uptake that differed from previously recognized populations, clarifying the underlying causes of suboptimal treatment rates. The optimized recall strategy significantly improved diagnosis and treatment rates, facilitating province- level HCV elimination."

Clinical • Real-world • Real-world evidence • Hepatitis C • Hepatology • Inflammation

A Box-Behnken design-assisted RP-HPLC method development and optimization for simultaneous determination of four antiviral drugs in pharmaceutical dosage forms. (PubMed, Sci Rep) - "In this study, we developed and optimized a reversed-phase high-performance liquid chromatography (RP-HPLC) method to measure four repurposed antiviral drugs: favipiravir, sofosbuvir, ledipasvir, and remdesivir. The sustainability of the proposed method was comprehensively evaluated using AGREE, MoGAPI, BAGI, and RAPI tools to assess its greenness, blueness, and whiteness. The proposed method offers a practical and efficient analytical platform for quality control laboratories, enabling reliable routine analysis of multiple antiviral agents in pharmaceutical products, particularly for post-pandemic preparedness and therapeutic surveillance."

Journal • Infectious Disease • Novel Coronavirus Disease

Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia (APASL 2026) - No abstract available

Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

Treatment Outcomes of HCV Genotype 1b with Ledipasvir/Sofosbuvir and the Role of Resistance-Associated Substitutions in Mongolia (APASL 2026) - No abstract available

Clinical • Hepatitis C

Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye. (PubMed, Turk J Gastroenterol) - "Patients received the following treatments: Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD):706, Ledipasvir+Sofosbuvir:490, Sofosbuvir+Ribavirin:176, PrOD+Ribavirin:175, Ledipasvir+Sofosbuvir+Ribavirin:156, PrO+Ribavirin:32, and PrO:10. In two-thirds of the patients, the hepatic inflammation is moderate to severe, and fibrosis is moderate to advanced in half of them. Patients' characteristics suggest that HCV infection is often not diagnosed or treated until patients present with moderate-to-severe stage, indicating that diagnostic and therapeutic approaches should be used more effectively."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

FRI-STC: Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC (clinicaltrials.gov) - P3 | N=150 | Completed | Sponsor: National Hepatology & Tropical Medicine Research Institute | Unknown status ➔ Completed

Trial completion • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review. (PubMed, Eur J Clin Pharmacol) - No abstract available

HEOR • Journal • Review • Hepatitis C • Infectious Disease • Inflammation

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study. (PubMed, Pediatr Nephrol) - "SOF/LDV was found to be effective in the treatment of HCV in children and adolescents with CKD on HD with SVR12 86.4%, with no serious adverse events recorded."

Journal • Observational data • Chronic Kidney Disease • Hepatitis C • Nephrology • Pediatrics • Renal Disease

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients. (PubMed, Hepatol Res) - "Retreatment with SOF/VEL + RBV, GLE/PIB for 12 weeks, or SOF/LDV achieved high SVR12 rates, indicating that effective viral eradication is feasible using currently available DAA regimens even after prior treatment failure."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Micro-elimination of Hepatitis C virus (HCV) infection in the General Population Cohort in rural Uganda: Long-term follow-up to assess feasibility and outcomes of a screening and treatment intervention. (PubMed, J Clin Virol) - "Among individuals offered DAA treatment, acceptance and cure rate were high. In this setting, HCV infection likely contributed to mortality, and affected older adults and migrants, suggesting these groups might be priorities for future micro-elimination programmes."

Journal • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Generic vs brand forms of direct acting antivirals for hepatitis C virus treatment in Egyptian children. (PubMed, World J Hepatol) - "The use of generic SOF/LED in HCV infected children is safe and effective. It is comparable to the brand form at a reduced price and represents an affordable and effective alternative."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation